drugset

drugset / Trial / NCT00684099

Docetaxel/Pemetrexed as 1st Line Treatment in Patients With Non Small Cell Lung Cancer (NSCLC)

NCT00684099 ↗

Phase 1/2 Completed 70 enrolled Hellenic Oncology Research Group University Hospital of Crete · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This trial will determine the maximum tolerated dose the recommended phase II dose and the efficacy of this combination in locally advanced or metastatic NSCLC patients

Timeline

Start: 2006-05
Primary completion: 2009-05
Completion: 2009-05

Publications

Kotsakis A, Agelaki S, Vardakis N, Stathopoulos G, Vamvakas L, Kalykaki A, Kentepozidis N, Kontopodis E, Sfakiotaki G, Mavroudis D, Georgoulias V. A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer. Cancer Chemother Pharmacol. 2011 Aug;68(2):415-22. doi: 10.1007/s00280-010-1508-5. Epub 2010 Nov 11.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Docetaxel	Small molecule	65 mg/m2	Intravenous
Subject	Docetaxel	Small molecule	75 mg/m2	Intravenous
Subject	Docetaxel	Small molecule	85 mg/m2	Intravenous
Subject	Pemetrexed	Small molecule	400 mg/m2	Intravenous
Subject	Pemetrexed	Small molecule	500 mg/m2	Intravenous
Subject	Pemetrexed	Small molecule	550 mg/m2	Intravenous

Indications